Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome
暂无分享,去创建一个
C. Heeschen | M. Simoons | E. Boersma | R. Oemrawsingh | K. M. Akkerhuis | S. Fichtlscherer | C. Hamm | S. Baldus | T. Lenderink | C. W. Hamm | K. Akkerhuis
[1] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[2] J. Ornato,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.
[3] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[4] R. Califf,et al. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. , 2006, Journal of the American College of Cardiology.
[5] R. Leboeuf,et al. Expression of Human Myeloperoxidase by Macrophages Promotes Atherosclerosis in Mice , 2005, Circulation.
[6] A. Luttun,et al. Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation , 2005, Circulation.
[7] C. Heeschen,et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. , 2005, Journal of the American College of Cardiology.
[8] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[9] François Mach,et al. Inflammation and Atherosclerosis , 2004, Herz.
[10] Marlene Goormastic,et al. Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans , 2004, Circulation.
[11] C. Heeschen,et al. Prognostic value of placental growth factor in patients with acute chest pain. , 2004, JAMA.
[12] E. Topol,et al. Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.
[13] C. Heeschen,et al. Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.
[14] Yibing Yan,et al. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease , 2003, Current opinion in hematology.
[15] H. Drexler,et al. Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. , 2003, The American journal of cardiology.
[16] C. Heeschen,et al. Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.
[17] M. Sabatine,et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. , 2003, Journal of the American College of Cardiology.
[18] C. Heeschen,et al. Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.
[19] C P Price,et al. Cumulative risk assessment in unstable angina: clinical, electrocardiographic, autonomic, and biochemical markers , 2003, Heart.
[20] A. Luttun,et al. Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1) , 2002 .
[21] Nader Rifai,et al. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.
[22] K. Bailey,et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. , 2001, The New England journal of medicine.
[23] K. Mackway-Jones,et al. Is it possible to exclude a diagnosis of myocardial damage within six hours of admission to an emergency department? Diagnostic cohort study , 2001, BMJ : British Medical Journal.
[24] C. Heeschen,et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.
[25] C. Heeschen,et al. Soluble CD 40 Ligand in Acute Coronary Syndromes , 2003 .
[26] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[27] A. Luttun,et al. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. , 2002, Annals of the New York Academy of Sciences.